In 2012, approximately 240 000 women worldwide were diagnosed with an advanced ovarian, epithelial, fallopian tube, or primary peritoneal cancer.
1 Approximately 75% of women have Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) stage III or IV cancer at diagnosis. Initial management involves the combination of surgical cytoreduction and systemic chemotherapy. Carboplatin and paclitaxel constitute the universal standard regimen in the management of ovarian cancer, with a response rate of approximately 65%, median progression-free survival (PFS) ranging from 16 to 21 months, and median overall survival (OS) ranging from 32 to 57 months.
2 Currently, OS is the criterion standard for the evaluation of treatment, but both OS and PFS have led to drug approvals by regulatory agencies (the US Food and Drug Administration and European Medicines Agency). Progression-free survival gives an earlier assessment of antitumor activity, requires smaller sample sizes, and is not affected by postprogression therapy. The Gynecologic Cancer InterGroup (GCIG)
3 recommended that PFS can serve as a primary end point instead of OS, provided that secondary end points, such as quality of life, support the superiority of the investigated treatment. Evidence of the validity of PFS as a surrogate marker of OS in the modern era of different treatment types is lacking. In 2009, Buyse
4 showed that PFS was a good surrogate marker of OS in ovarian cancer, but that study was limited to 4 trials that investigated standard cytotoxic regimens (cyclophosphamide plus cisplatin vs cyclophosphamide plus doxorubicin hydrochloride [Adriamycin] plus cisplatin) and used the older World Health Organization definition of progression. A correlation at the individual level measured by a Kendall τ of 0.84 (95% CI, 0.83-0.85) and at the group level measured by a Pearson correlation of 0.95 (95% CI, 0.82-1.00) was found. In these trials, treatment effect on PFS was associated with treatment effect on OS.